Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prime Medicine Inc (NQ: PRME )

3.730 +0.180 (+5.07%)
Streaming Delayed Price Updated: 3:09 PM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine Inc

< Previous 1 2 3 Next >
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
From Prime Medicine, Inc.
Via GlobeNewswire
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
Analyst Ratings for Prime Medicine
Via Benzinga
2 Cathie Wood Stocks That Could Be Hidden Gems
These two biotech stocks could deliver life-altering returns for long-term investors. 
Via The Motley Fool
Morgan Stanley Reports Q4 Results, Joins Boeing, Alcoa And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
Better Growth Stock: Archer Aviation or Prime Medicine?
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years
This gene-editing company could sport a best-in-class platform. 
Via The Motley Fool
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
DISH Network, Goodyear And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
From Prime Medicine, Inc.
Via GlobeNewswire
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst
BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ: PRME), a preclinical-stage company focused on developing therapies based on prime editing. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 386 stocks made new 52-week lows. 
Via Benzinga
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.